Companies /Healthcare

Beam Therapeutics Inc

NASDAQ: BEAM Biotechnology
$30.59
â–² $0.40 (+1.32%) today
Markets open · 2:40pm ET

Q2 2025 Earnings

Reported Aug 5, 2025, 7:07am ET · SEC source
$-1.00
Beat +8.37%
EPS · est. $-1.09
$8.5M
Miss −36.31%
Revenue · est. $13.3M
+8.6%
Beating market
BEAM vs S&P since report
1 quarter
Consecutive EPS misses

Market Reaction

% change · around the report
−9%−6%−3%0Aug 5Aug 6report 7:07am ETearnings−0.1%−6.1%
−9%−6%−3%0Aug 5Aug 6earnings−0.1%−6.1%
BEAM −6.1%S&P 500 −0.1%
−9%−6%−3%0Aug 5Aug 6report 7:07am ETearnings−0.1%−6.1%
−9%−6%−3%0Aug 5Aug 6earnings−0.1%−6.1%
BEAM −6.1%NASDAQ −0.1%
−10%−5%0Aug 4Aug 13report 7:07am ETearnings+1.9%−11.8%
−10%−5%0Aug 4Aug 13earnings+1.9%−11.8%
BEAM −11.8%S&P 500 +1.9%
−10%−5%0Aug 4Aug 13report 7:07am ETearnings+2.8%−11.8%
−10%−5%0Aug 4Aug 13earnings+2.8%−11.8%
BEAM −11.8%NASDAQ +2.8%
−2.20%
Day of report
−2.14%
Next session
−9.84%
One week
+11.66%
30 days

S&P 500 over the same 30 days: +3.07%.

Did BEAM Beat Earnings? Q2 2025 Results

Beam Therapeutics delivered a mixed second quarter, beating Wall Street's loss expectations while falling well short on revenue as the gene editing company continues funneling capital into its clinical pipeline. The company posted a loss of $1.00 per share, coming in 8.37% better than the consensus estimate of $1.09, but revenue of $8.47 million missed forecasts by 36.31% and slid 28.1% from the year-ago quarter's $11.77 million, reflecting lower license and collaboration payments. The primary driver of the wider absolute net loss, which widened to $102.29 million from $91.05 million a year ago, was a 17% surge in R&D spending to $101.76 million as Beam advanced both BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-101 for sickle cell disease through active Phase 1/2 trials. Analysts tracking the company have maintained a constructive view on the pipeline's potential, citing the FDA's RMAT designation for BEAM-302 as a positive signal. With $1.15 billion in cash, Beam projects its runway extending into 2028, with key data readouts for BEAM-101 expected by year-end and a BEAM-302 clinical update targeted for early 2026.

Key Takeaways
  • Increased R&D spending driven by advancing multiple clinical-stage programs
  • Higher other income partially offsetting operating losses
  • Capital raises in early 2025 significantly strengthening balance sheet

“In the first half of 2025, we made significant clinical, operational and regulatory progress across each of our high-priority programs, and we aim to harness this momentum heading into key catalysts at the end of 2025 and early next year. We have now dosed 30 patients in the BEACON trial of BEAM-101, which has a potential best-in-class profile as a one-time therapy for severe sickle cell disease, marking an important milestone on our path to a BLA filing. We look forward to sharing additional data from this trial later this year.”

Beam Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Beam expects its cash, cash equivalents, and marketable securities of approximately $1.2 billion as of June 30, 2025, to fund anticipated operating expenses and capital expenditure requirements into 2028. Key upcoming catalysts include: data from Parts A and B of the BEAM-302 Phase 1/2 trial and a clinical development update in early 2026; updated BEACON Phase 1/2 trial data for BEAM-101 by end of 2025; continued dosing in the BEAM-301 Phase 1/2 trial for GSDIa; and initiation of a Phase 1 healthy volunteer trial for BEAM-103 (ESCAPE monoclonal antibody) by end of 2025.

BEAM YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-150,000,000$-100,000,000$-50,000,000$0$11.8M$8.5MRevenue$-140,593,260$-120,151,000Operating Income$-116,690,623$-102,291,000Net Income
$-150,000,000$-100,000,000$-50,000,000$0RevenueOperating IncomeNet Income

Figures from SEC filings and company reports. Not investment advice.